Long non‐coding RNAE330013P06 promotes progression of breast cancer with type 2 diabetes

Abstract

Background In previous research, we found diabetes rather than obesity was an independent risk factor of breast cancer. However, why diabetes could lead to increased risk of breast cancer patients remains elusive. Long non‐coding RNAE330013P06 has been shown to be upregulated in diabetes, and long non‐coding RNAs generally promote progression of cancer. Methods About 200 specimens of breast patients were obtained in previous clinical trial; 34 samples diagnosed as type 2 diabetes in breast cancer patient were enrolled in this research. Blood samples from 36 patients diagnosed as breast cancer without diabetes; 35 diabetic patients and 35 healthy peoples were obtained as control. All blood samples were measured by quantitative real‐time PCR (qRT‐PCR). Invasion and migration were tested by Transwell assay. Cell proliferation assay was tested by CCK‐8. Protein analysis was determined by Western blot. Results Compared with breast cancer patients without diabetes, diabetic patients without breast cancer and healthy peoples, LncRNAE330013P06 was upregulated in breast cancer patient with diabetes. Furthermore, of 34 breast patients, high LncRNAE330013P06 expression was significantly associated with family history, tumor‐node‐metastasis stage and lymph node metastasis. E33 promoted cancer cell growth in vitro via downregulation of P53. Conclusion Upregulation of LncRNAE330013P06 driven by type 2 diabetes is one of the factors which promoted progression of breast cancer.

Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy

“…Another study showed that expression levels of miR-124a and miR-30d were the highest in the blood of breast cancer patients with T2DM compared to the T2DM patients and breast cancer patients and the lowest in the healthy group, indicating that miR-124a and miR-30d could contribute to the development of breast cancer in patients with T2DM [144]. In addition, found to be upregulated in the plasma of T2DM patients, high serum LncRNAE330013P06 expression levels were also associated with breast cancer progression, family history, and lymph node metastasis compared with non-T2DM patients, T2DM patients without breast cancer, and healthy donors [145]. However, so far, no circulating miRNA and LncRNA expression profiling has been correlated to TNBC in T2DM patients, in comparison to TNBC patients and T2DM patients.…”